It goes with the territory with Pharma companies - particularly on AIM.
REDX will come good eventually - they have much more than most in the pipeline and are well managed - but we will have to wait at least 3 or 4 years I guess.
SP is still good value at 39p but be prepared for more dilution.
I think that it is all or northing with Pharma shares - they can just stagnate or collapse with bad news.
PRTC has a lot going on with plenty of different strings to its bow, so hopefully something will ignite soon and give us a good return.
Also it is not AIM.
Yes, the same here. ENQ did a 5 for 9 offer last October at 23p - the shares are now 49p.
I think these offers are usually anticipated and priced into the SP, so when they are over the SP responds with a good rise.
I just considered it a top up and a vote of confidence in the company.
It works out at about 2.5p discount on the buying price at the moment and even if the SP does fall a bit I don't think it will stay low for long.
I reckon we can expect around 50p in a few months but DYOR.
That is the problem I don't think anyone actually knows - we need clarity here!!
Potential NASDAQ investors may not like what they see if VRP don't take a grip on things.
Please lets see an RNS with a clear concise answers to investors concerns - we simply want to know what the hell is going on!!
The two last trades of the day at 16.28 could have been shorts closing.
Maybe this whole week has been shorts taking advantage of the uncertainty around consolidation [in investors minds] and the lack of clarity going forward with regards to dilution and the NASDAQ listing.
In other words opportunist traders taking investors for a ride!!
With the low trading volumes here, would the SP be boosted significantly if one of the larger shareholders started buying?
Following from that would it not be imperative from the large investors point of view to save guard their investment?
Dilution can actually be the making of a company and inject real value into the SP.
Last October my ENQ shares were trading around the 25p mark - dilution was announced with an open offer 4 new shares for 9 old shares at a price of 23.5p for the new shares.
Add some good news - a rise in the oil price and the capital raised spent on new assets - and the price now is 48p and likely to go a lot higher.
The thing is VRP needs capital - you have to accept dilution when you invest in growth companies.
Having invested here for the potential I think that VRP is still a sound investment.
It may be at a 52 week low but that can easily be reversed by good news and entry to the NASDAQ.
As for more dilution, if it realises the potential of a blockbuster drug then it must be a necessary step for VRP and all investors - the pie gets bigger!
I guess in the short term it is all about sentiment - not a penny share anymore - joining the NASDAQ soon - blockbuster drug in the wings and all that.
So the sentiment is good - share price will rise - maybe £1.65 by Friday?
In the longer term this is AIM - anything could happen!!!